Synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome
Conditions
Interventions
1.5mg treatment group:1.5mg/(kg*d) dose of oral Tripterygium wilfordii Hook F, taking in 2-3 times a day, post meal
dosage starts to reduce after 5-week treatment until reaching 1.0mg/(kg*d) at the end of 12-week follow-up
1.0mg treatment group:1.0mg/(kg*d) dose of oral Tripterygium wilfordii Hook F, taking in 2-3 times a day, post meal
dosage remains constant for 12 weeks
Sponsors
Peking Union Medical College Hospital
Eligibility
Sex/Gender
All
Age
29 Years to 66 Years
Inclusion criteria
Inclusion criteria: 1) Aged 18–70 years; 2) In accordance with the diagnostic criteria of SAPHO reported by Kahn in 2003; 3) ASDAS-CRP=1.3 4) VAS=4.
Exclusion criteria
Exclusion criteria: 1) Pregnant or lactating women; 2) With a desire to have children; 3) csDMARDs or biological therapy within 3 months before recruitment; 4) Severe cardiac, hepatic, renal dysfunction; 5) Significant abnormalities in hematology, including anemia, thrombocytopenia, leukopenia.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline in ASDAS; | — |
Secondary
| Measure | Time frame |
|---|---|
| The proportion of patients achieving VAS50;The proportion of patients achieving BASDAI50;The proportion of patients achieving ASDAS2.1, ASDAS1.3, ASDAS-CII, ASDAS-MI;Change from baseline in global bone pain;Change from baseline in BASDAI; | — |
Countries
China
Contacts
Public ContactChen Li
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Outcome results
None listed